Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/13/2025

Apixaban Dosing for Pulmonary Thromboembolism

Efficacy and Safety

  • The American College of Cardiology recommends apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily for 6 months) as a treatment option for pulmonary thromboembolism, which was found to be non-inferior to enoxaparin/warfarina in preventing recurrent pulmonary thromboembolism or death related to pulmonary thromboembolism (2.3% vs 2.7%) 1
  • The incidence of major bleeding was significantly lower with apixaban (0.6% vs 1.8%; relative risk 0.31; P<0.001) 1

Dosing Considerations

  • The American Heart Association notes that apixaban dosing for pulmonary thromboembolism should not be confused with dosing for atrial fibrillation, which is different (5 mg twice daily or 2.5 mg twice daily with reduction criteria) 2, 3

Limitations and Precautions

  • The evidence for apixaban use in patients with active cancer is limited, with only 2.7% of patients with cancer included in the AMPLIFY trial, leading some panels to not recommend apixaban as first-line treatment in this population 1